基于PK/PD模型对恩诺沙星可溶性粉在鸡混饮给药方案的药效再评价

doi:10.11843/j.issn.0366-6964.2022.09.034

摘要/Abstract

摘要： 旨在对不同日龄雏鸡开展恩诺沙星可溶性粉混饮给药的药动学研究，并利用获得的药动学参数通过PK/PD模型结合Monte Carlo模拟（Monte Carlo simulation，MCS）评价恩诺沙星可溶性粉推荐给药方案的合理性。分别在1、7和14日龄雏鸡进行恩诺沙星可溶性粉75 mg·L^-1（以恩诺沙星计）混饮给药，按预定时间点采集血样，采用经验证的HPLC法测定各时间点每只鸡的血药浓度，拟合药动学参数。将获得的药动学参数与美国临床和实验室标准协会（CLSI）给出的恩诺沙星对禽大肠杆菌的敏感性折点值（0.25 μg·mL^-1）结合计算PK/PD参数，并通过MCS获得当前给药方案在大肠杆菌不同MIC分布下的达标率（target attainment rate，TAR）。结果显示，1、7和14日龄雏鸡3个处理组在第0天达峰浓度（C_max）分别为0.561、0.564和0.550 μg·mL^-1，24 h曲线下面积（AUC_0-24）分别为8.85、9.85和9.27 μg·h·mL^-1；3个处理组给药第4天C_max分别为0.599、0.550和0.487 μg·mL^-1，平均稳态血药浓度（C_avg）分别为0.513、0.493和0.432 μg·mL^-1，AUC_0-24分别为12.31、11.82和10.37 μg·h·mL^-1，C_max/MIC分别为2.40、2.20和1.95，C_avg/MIC分别为2.05、1.97和1.73，AUC_0-24/MIC分别为49.24、47.28和41.48。恩诺沙星对MIC≤0.25 μg·mL^-1的大肠杆菌临床分离株，1、7和14日龄雏鸡给药期间TAR为75.01%～76.11%。以上结果表明，恩诺沙星可溶性粉按目前的推荐给药方案对敏感菌PK/PD参数比值和TAR均达不到预期，不仅杀菌效果有限，且易诱导细菌产生耐药性。

关键词: 恩诺沙星, PK/PD模型, Monte Carlo模拟, 雏鸡

Abstract: The pharmacokinetics of enrofloxacin soluble powder in the drinking water were investigated in chicks of various ages and the PK/PD model combined with Monte Carlo simulation (MCS) was used to evaluate the rationality of enrofloxacin soluble powder administration by the recommended regimen. Chicks were given 75 mg·L^-1 of enrofloxacin soluble powder (calculated by enrofloxacin) at 1, 7 and 14 days of age. At predefined time intervals, blood samples were obtained, the plasma concentration of enrofloxacin was measured by HPLC, and pharmacokinetic parameters were calculated. PK/PD parameters were calculated by combining the pharmacokinetic parameters with the breakpoint (0.25 μg·mL^-1) of enrofloxacin against Escherichia coli in poultry obtained by Clinical and Laboratory Standards Institute (CLSI), and the target attainment rate (TAR) of the current administration regimen under different MIC ranges of Escherichia coli was obtained by MCS. The results showed that C_max of chicks at 1, 7 and 14 days of age were 0.561, 0.564 and 0.550 μg·mL^-1 on day 0 of administration, and AUC_0-24 were 8.85, 9.85 and 9.27 μg·h·mL^-1, respectively. C_max of chicks at 1, 7, and 14 days of age on day 4 of administration were 0.599, 0.550 and 0.487 μg·mL^-1, C_a_vg were 0.513, 0.493 and 0.432 μg·mL^-1; AUC_0-24were 12.31, 11.82and 10.37 μg·h·mL^-1; C_max/MIC were 2.40, 2.20 and 1.95; C_avg/MIC were 2.05, 1.97 and 1.73; AUC_0-24/MIC were 49.24, 47.28 and 41.48, respectively. When the MIC of enrofloxacin against clinical isolates of Escherichia coli within 0.25 μg·mL^-1, TAR varied from 75.01 percent to 76.11 percent at 1, 7, and 14 days of age. The results revealed that enrofloxacin soluble powder failed to achieve the PK/PD parameter ratio and TAR of sensitive bacteria as expected by the currently suggested regimen, which not only limited bactericidal effect, but also easy to induce bacterial drug resistance.

Key words: enrofloxacin, PK/PD model, Monte Carlo simulation, chick

中图分类号:

S859.7

高嫣珺, 王美红, 聂雅, 王震, 卜仕金. 基于PK/PD模型对恩诺沙星可溶性粉在鸡混饮给药方案的药效再评价[J]. 畜牧兽医学报, 2022, 53(9): 3199-3207.

GAO Yanjun, WANG Meihong, NIE Ya, WANG Zhen, BU Shijin. Reevaluation of the Efficacy of Enrofloxacin Soluble Powder Mixed Drink Administration Regimen in Chicken by Modelling of Pharmacokinetic and Pharmacodynamic Data[J]. Acta Veterinaria et Zootechnica Sinica, 2022, 53(9): 3199-3207.

参考文献 31

[1]	MAJALEKAR P P, SHIROTE P J. Fluoroquinolones:blessings or curses[J]. Curr Drug Targets, 2020, 21(13):1354-1370.
[2]	KANG J, HOSSAIN M A, PARK H C, et al. Pharmacokinetic and pharmacodynamic integration of enrofloxacin against Salmonella Enteritidis after administering to broiler chicken by per-oral and intravenous routes[J]. J Vet Sci, 2019, 20(2):e15.
[3]	宁官保, 牛艺儒, 张鼎, 等. 鸡源大肠杆菌耐药性分析及中药对大肠杆菌耐药性消除作用的研究[J]. 畜牧兽医学报, 2015, 46(6):1018-1025.NING G B, NIU Y R, ZHANG D, et al. Studies on the drug resistance of chicken isolated Escherichia coli and role of traditional Chinese medicines in the drug resistance elimination[J]. Acta Veterinaria et Zootechnica Sinica, 2015, 46(6):1018-1025. (in Chinese)
[4]	秦春芝, 徐怀英, 黄迪海, 等. 山东省禽源致病性大肠杆菌流行病学监测及耐药模式分析[J]. 中国动物检疫, 2021, 38(8):16-21, 62.QIN C Z, XU H Y, HUANG D H, et al. Epidemiological surveillance of avian pathogenic Escherichia coli in Shandong province and it's antimicrobial resistance analysis[J]. China Animal Health Inspection, 2021, 38(8):16-21, 62. (in Chinese)
[5]	高强, 薛瑞林, 李守湖, 等. 鸡源大肠杆菌和沙门氏菌的分离鉴定及耐药分析[J]. 中国兽药杂志, 2020, 54(11):14-21.GAO Q, XUE R L, LI S H, et al. Study on the antibacterial effect of compound Chinese herbal medicine on E. coli and Salmonella from chicken[J]. Chinese Journal of Veterinary Drug, 2020, 54(11):14-21. (in Chinese)
[6]	GUO K X, ZHAO Y, CUI L Q, et al. Longitudinal surveillance and risk assessment of resistance in Escherichia coli to enrofloxacin from a large-scale chicken farm in Hebei, China[J]. Antibiotics, 2021, 10(10):1222.
[7]	徐耀辉, 邓同炜, 齐亚如, 等. 三黄种鸡场孵化死胚中沙门菌的分离鉴定与耐药性分析[J]. 畜牧兽医学报, 2018, 49(5):1081-1088.XU Y H, DENG T W, QI Y R, et al. Isolation, identification and antimicrobial resistance of Salmonella from dead chicken embryos in Sanhuang breeder farms[J]. Acta Veterinaria et Zootechnica Sinica, 2018, 49(5):1081-1088. (in Chinese)
[8]	ROTH N, KÄSBOHRER A, MAYRHOFER S, et al. The application of antibiotics in broiler production and the resulting antibiotic resistance in Escherichia coli:a global overview[J]. Poul Sci, 2019, 98(4):1791-1804.
[9]	KRISHNASAMY V, OTTE J, SILBERGELD E. Antimicrobial use in Chinese swine and broiler poultry production[J]. Antimicrob Resist Infect Control, 2015, 4(1):17.
[10]	HVISTENDAHL M. China takes aim at rampant antibiotic resistance[J]. Science, 2012, 336(6083):795.
[11]	中华人民共和国农业农村部. 2020年中国兽用抗菌药使用情况报告[J/OL]. 兽医公报, 2021, 23(9):33-36.[2022-06-23]. http://www.moa.gov.cn/gk/sygb/202111/P020211104353940540082.pdfMinistry of Agriculture and Rural Affairs of the People's Republic of China. 2020 Annual report on the use of veterinary antibiotics in China[J/OL]. Official Veterinary Bulletin, 2021, 23(9):33-36.[2022-06-23]. http://www.moa.gov.cn/gk/sygb/202111/P020211104353940540082.pdf(in Chinese)
[12]	PRIVALSKY T M, SOOHOO A M, WANG J H, et al. Prospects for antibacterial discovery and development[J]. J Am Chem Soc, 2021, 143(50):21127-21142.
[13]	WOOLHOUSE M, WARD M, VAN BUNNIK B, et al. Antimicrobial resistance in humans, livestock and the wider environment[J]. Philos Trans R Soc B:Biol Sci, 2015, 370(1670):20140083.
[14]	BROWN E D, WRIGHT G D. Antibacterial drug discovery in the resistance era[J]. Nature, 2016, 529(7586):336-343.
[15]	VIVAS R, BARBOSA A A T, DOLABELA S S, et al. Multidrug-resistant bacteria and alternative methods to control them:an overview[J]. Microb Drug Resist, 2019, 25(6):890-908.
[16]	TOUTAIN P L, LEES P. Integration and modelling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine[J]. J Vet Pharmacol Ther, 2004, 27(6):467-477.
[17]	BELEW S, KIM J Y, HOSSAIN A, et al. Pharmacokinetics of marbofloxacin after intravenous and intramuscular administration in Hanwoo, Korean native cattle[J]. J Vet Med Sci, 2015, 77(3):327-329.
[18]	DRUSANO G L, LOUIE A. Breakpoint determination when multiple organisms are tested for effect targets[J]. Eur J Pharm Sci, 2019, 130:196-199.
[19]	DRUSANO G L, PRESTON S L, HARDALO C, et al. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint[J]. Antimicrob Agents Chemother, 2001, 45(1):13-22.
[20]	FREI C R, WIEDERHOLD N P, BURGESS D S. Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation[J]. J Antimicrob Chemother, 2008, 61(3):621-628.
[21]	MOUTON J W, DUDLEY M N, CARS O, et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs:an update[J]. J Antimicrob Chemother, 2005, 55(5):601-607.
[22]	AMBROSE P G, GRASELA D M. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs:fluoroquinolone pharmacodynamics against Streptococcus pneumoniae[J]. Diagn Microbiol Infect Dis, 2000, 38(3):151-157.
[23]	CLSI. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals. 5th ed. CLSI supplement VET01S[M/OL]. Clinical and Laboratory Standards Institute, 2020.[2022-06-23].http://clsivet.org/Dashboard.aspx.
[24]	SANG K N, HAO H H, HUANG L L, et al. Pharmacokinetic-pharmacodynamic modeling of enrofloxacin against Escherichia coli in broilers[J]. Front Vet Sci, 2016, 2:80.
[25]	BLASER J, STONE B B, GRONER M C, et al. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance[J]. Antimicrob Agents Chemother, 1987, 31(7):1054-1060.
[26]	THOMAS J K, FORREST A, BHAVNANI S M, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy[J]. Antimicrob Agents Chemother, 1998, 42(3):521-527.
[27]	TOUTAIN P L, BOUSQUET-MÉLOU A, MARTINEZ M. AUC/MIC:a PK/PD index for antibiotics with a time dimension or simply a dimensionless scoring factor?[J]. J Antimicrob Chemother, 2007, 60(6):1185-1188.
[28]	BOOKER B M, SMITH P F, FORREST A, et al. Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype Typhi[J]. Antimicrob Agents Chemother, 2005, 49(5):1775-1781.
[29]	AMBROSE P G, BHAVNANI S M, RUBINO C M, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy:it's not just for mice anymore[J]. Clin Infect Dis, 2007, 44(1):79-86.
[30]	CRAIG W A. Pharmacodynamics of antimicrobials:general concepts and applications[M]//NIGHTINGALE C H, MURAKAWA T, AMBROSE P G. Antimicrobial Pharmacodynamics in Theory and Clinical Practice. 2nd ed. Boca Raton:CRC Press, 2007:1-20.
[31]	ANDES D, CRAIG W A. Animal model pharmacokinetics and pharmacodynamics:a critical review[J]. Int J Antimicrob Agents, 2002, 19(4):261-268.